FDA reviewers mixed on brodalumab's safety

In briefing documents released ahead of an advisory committee meeting, FDA reviewers focused on two main safety concerns with psoriasis compound brodalumab (KHK4827) from Valeant Pharmaceuticals International Inc. (TSX;VRX; NYSE:VRX) -- suicidal ideation and behavior (SIB) and risk of cardiovascular events. The reviewers were mixed

Read the full 457 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE